...
首页> 外文期刊>Advances in Interventional Cardiology: Postepy w Kardiologii Interwencyjnej >The mechanism and prognosis of vessel perforation following excimer laser coronary angioplasty in the new generation laser catheter era
【24h】

The mechanism and prognosis of vessel perforation following excimer laser coronary angioplasty in the new generation laser catheter era

机译:新一代激光导管时代的准分子激光冠状动脉成形术后血管穿孔的机制和预后

获取原文
           

摘要

Introduction Excimer laser coronary angioplasty (ELCA) was developed with the aim of improving the outcome of conventional balloon angioplasty [1]; therefore, its original target was limited to a very specific subset of lesions, such as saphenous vein graft, total occlusions, calcified lesions, ostial lesions, lesions greater than 20 mm in length, and balloon dilation failures [2–4]. However, an excimer laser, which can vaporize thrombus, suppress platelet aggregation, and ablate the underlying plaque, has recently been shown to be effective in patients with acute coronary syndrome (ACS) [5]. Although rare, vessel perforation is the most terrible complication of ELCA. Early studies regarding the complications of ELCA in its introductory era revealed that patients with vessel perforation were mainly treated via coronary artery bypass grafting (CABG) [6]; however, the necessity of CABG is decreasing as a result of technological advances, as well as improvements in intervention technique. Therefore, the prognosis of patients who were successfully treated for vessel perforation via ELCA without CABG is not fully addressed. Also, the risk factors related to ELCA-induced vessel perforation in the era of a new indication, ACS, and a new generation excimer laser catheter are unknown. Aim The purpose of this study was to investigate the current prognosis and mechanism of vessel perforation as induced by ELCA. Material and methods We retrospectively analyzed patients who underwent ELCA at Ogaki Municipal Hospital between February 2016 and December 2018. This study was approved by the research review board of Ogaki Municipal Hospital and conducted according to the Helsinki Declaration. Because of its retrospective nature, written informed consent from the participants was waived; however, we excluded the patients who refused to participate in the study. A pulse-wave xenon chloride excimer laser (Spectranetics CVX-300, Spectranetics, Colorado Springs, Colorado) was applied. It had a 308 nm wavelength, a pulse duration of 135 ns, and an output of 165 mJ/pulse. The laser catheters consisted either of concentric tips (sizes of 0.9, 1.4, 1.7, and 2.0 mm; Vitesse C, Spectranetics) or eccentric tips (sizes 1.7 and 2.0 mm; Vitesse E, Spectranetics). Initial energy parameters for lasing were set at a fluence of 45 mJ/mm2 and 25 Hz and increased if ablation resistance was encountered. The type and size of the laser catheter were...
机译:前言准分子激光冠状动脉成形术(ELCA)的开发旨在改善常规球囊成形术的疗效[1]。因此,其最初的靶标仅限于非常特殊的病变子集,例如大隐静脉移植,总闭塞,钙化病变,眼部病变,长度大于20 mm的病变以及球囊扩张失败[2-4]。然而,最近已证明可激化血栓,抑制血小板聚集并消融潜在斑块的准分子激光在急性冠脉综合征(ACS)患者中有效[5]。尽管很少见,但血管穿孔是ELCA最可怕的并发症。早期关于ELCA引入期并发症的研究表明,血管穿孔患者主要通过冠状动脉搭桥术(CABG)进行治疗[6]。然而,由于技术的进步以及干预技术的改进,CABG的必要性正在降低。因此,没有通过CABG通过ELCA成功治疗血管穿孔的患者的预后尚未得到充分解决。同样,在新的适应症,ACS和新一代的准分子激光导管时代,与ELCA引起的血管穿孔有关的危险因素尚不清楚。目的本研究的目的是研究由ELCA引起的血管穿孔的当前预后及其机制。材料和方法我们回顾性分析了2016年2月至2018年12月在大垣市立医院接受ELCA治疗的患者。该研究得到大垣市立医院研究审查委员会的批准,并根据赫尔辛基宣言进行。由于具有追溯性,因此放弃了参与者的书面知情同意;但是,我们排除了拒绝参加该研究的患者。使用脉冲波氯化氙准分子激光器(Spectranetics CVX-300,Spectranetics,科罗拉多斯普林斯,科罗拉多州)。它的波长为308 nm,脉冲持续时间为135 ns,输出功率为165 mJ /脉冲。激光导管由同心尖端(尺寸为0.9、1.4、1.7和2.0毫米; Vitesse C,Spectranetics)或偏心尖端(尺寸为1.7和2.0 mm; Vitesse E,Spectranetics)组成。激光的初始能量参数设置为45 mJ / mm2和25 Hz的能量密度,如果遇到抗烧蚀性,则增加。激光导管的类型和尺寸为...

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号